Log in to search using one of your social media accounts:

 

Regeneron CEO says fears over Eylea 'greatly exaggerated'

(Reuters) - Fears of the demise of blockbuster eye drug Eylea were "greatly exaggerated," Regeneron Pharmaceuticals Inc's chief executive said on Thursday, after the treatment and new eczema drug Dupixent powered the company's fourth-quarter results.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

(Reuters Health) - Children with eczema whose bath water contains added moisturizers may get no more relief from the itchy skin condition than they would without the extra bath products, a recent experiment suggests.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
This report demonstrates that sampling and detection of IL-36 γ protein by non-invasive tape stripping of skin lesion provides a highly sensitive and selective diagnostic for psoriatic inflammation.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
Conclusion There is limited evidence to suggest that the off-label use of montelukast is effective in treating moderate-to-severe AD. Further research with larger study populations employing standardized endpoint measuring instrument is warranted to further investigate the off-label use of montelukast in AD treatment. Until then, the use of conventional treatments including optimal daily skin hydration should remain the mainstay in the  management of atopic dermatitis. In fact, for moderate-to-severe condition, steroid sparing immune-suppressants should still be used clinically until more effective and safer alte...
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research
With two decades of medical education, training, and research under my belt, I have finally reached the stage in my career when I can proudly state that I intentionally spray people in the face with live bacteria.
Source: CNN.com - Health - Category: Consumer Health News Source Type: news
AbstractPurpose of reviewWe hope that this review can assist in the classification, diagnosis, prevention, and treatment of a contact urticaria syndrome (CUS), a syndrome in which the understanding of such is still evolving.Recent findingsCUS and protein contact dermatitis (PCD) can be defined as an immediate inflammatory reaction of the skin following contact with an external substance. Erythema, wheals, and eczema, as well as other manifestations can occur as a result of this inflammatory reaction. Many low molecular weight substances and proteins are known to produce these immediate skin contact reactions. These reactio...
Source: Current Treatment Options in Allergy - Category: Allergy & Immunology Source Type: research
Condition:   Atopic Dermatitis Interventions:   Drug: Tralokinumab;   Drug: Placebos Sponsor:   LEO Pharma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
British Journal of Dermatology,Volume 178, Issue 5, Page 1007-1008, May 2018.
Source: British Journal of Dermatology - Category: Dermatology Authors: Source Type: research
British Journal of Dermatology,Volume 178, Issue 5, Page e354-e354, May 2018.
Source: British Journal of Dermatology - Category: Dermatology Authors: Source Type: research
ACTRESS and TV presenter Nadia Sawalha isn ’t known for being shy when it comes to talking through health issues many people would rather keep quiet about.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Updated Date: May 15, 2018 EST
Source: DailyMed Drug Label Updates - Category: Drugs & Pharmacology Source Type: alerts
More News: Eczema | Health